Swedish Orphan Biovitrum
Clinical trials sponsored by Swedish Orphan Biovitrum, explained in plain language.
Swedish Orphan Biovitrum
SOBI
NASDAQ STOCKHOLM
A biopharmaceutical company focused on rare diseases, now part of Sobi.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myelofibrosis patients with dangerous low platelet counts Results expected Oct 2026 (estimated)
- Weekly shot may shield joints in hemophilia a patients Results expected Nov 2026 (estimated)
- New hope for rare inflammatory disease: pacritinib trial begins Results expected Dec 2026 (estimated)
- Real-World data may unlock Pacritinib's true potential in myelofibrosis Results expected Jan 2027 (estimated)
- New clotting factor offers continued bleeding control for hemophilia a patients Results expected Mar 2027 (estimated)